MCID: MSN004
MIFTS: 38

Mesenchymal Cell Neoplasm

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Mesenchymal Cell Neoplasm

MalaCards integrated aliases for Mesenchymal Cell Neoplasm:

Name: Mesenchymal Cell Neoplasm 12 15 73
Benign Miscellaneous Mesenchymal Tumor 12
Mesenchymal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3350
NCIt 50 C6587 C7059

Summaries for Mesenchymal Cell Neoplasm

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic connective tissue that is capable of developing into connective tissue, such as bone, and cartilage, the lymphatic system, and the circulatory system.

MalaCards based summary : Mesenchymal Cell Neoplasm, also known as benign miscellaneous mesenchymal tumor, is related to malignant mesenchymoma and gastrointestinal stromal tumor. An important gene associated with Mesenchymal Cell Neoplasm is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and p70S6K Signaling. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mesenchymal Cell Neoplasm

Diseases related to Mesenchymal Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 malignant mesenchymoma 32.5 CALD1 EWSR1 KIT
2 gastrointestinal stromal tumor 31.9 CD34 KIT PDGFRA
3 carney triad 31.8 KIT PDGFRA
4 gallbladder sarcoma 31.7 CD34 KIT
5 inflammatory myofibroblastic tumor 31.3 ALK CLTC KIT RANBP2 TPM3 TPM4
6 histiocytoma 29.5 ALK EWSR1 KIT
7 mediastinal mesenchymal tumor 12.1
8 central nervous system mesenchymal non-meningothelial tumor 11.7
9 oncogenic osteomalacia 11.4
10 vaginal carcinosarcoma 11.2
11 ovarian carcinosarcoma 11.2
12 fetal lung interstitial tumor 11.1
13 paraganglioma and gastric stromal sarcoma 11.0
14 myoma 11.0
15 uterine carcinosarcoma 11.0
16 osteomalacia 10.5
17 perineurioma 10.3 ALK KIT
18 reticular perineurioma 10.3 KIT PDGFRA
19 sm-ahnmd 10.2 KIT PDGFRA
20 gastric leiomyosarcoma 10.2 KIT PDGFRA
21 endometrial small cell carcinoma 10.2 KIT PDGFRA
22 desmoid tumor 10.2 KIT PDGFRA
23 hypereosinophilic syndrome, idiopathic 10.2 KIT PDGFRA
24 pulmonary vein stenosis 10.2 KIT PDGFRA
25 lung adenoid cystic carcinoma 10.2 ALK KIT PDGFRA
26 heart sarcoma 10.2 KIT PDGFRA
27 neurilemmoma 10.2 KIT PDGFRA SMARCB1
28 malignant peripheral nerve sheath tumor 10.2 KIT PDGFRA SMARCB1
29 ovarian melanoma 10.2 CALD1 KIT
30 chronic eosinophilic leukemia 10.1 KIT PDGFRA TPM3
31 undifferentiated pleomorphic sarcoma 10.1 KIT PDGFRA
32 kidney rhabdoid cancer 10.1 EWSR1 SMARCB1
33 rhabdoid cancer 10.1 EWSR1 SMARCB1
34 childhood kidney cell carcinoma 10.1 ALK TPM3
35 extraosseous chondrosarcoma 10.1 EWSR1 SMARCB1
36 small cell sarcoma 10.1 CALD1 SMARCB1
37 pediatric fibrosarcoma 10.1 EWSR1 TPM3
38 synovium cancer 10.1 EWSR1 SMARCB1
39 gallbladder leiomyoma 10.1 CD34 KIT
40 lung leiomyosarcoma 10.1 CD34 KIT
41 liver leiomyoma 10.1 CD34 KIT
42 extracutaneous mastocytoma 10.1 CD34 KIT
43 sarcoma 10.1
44 small intestine leiomyosarcoma 10.1 CD34 KIT
45 small intestinal sarcoma 10.0 CD34 KIT
46 prostate leiomyosarcoma 10.0 CD34 KIT
47 neurofibromatosis, type i 10.0 KIT PDGFRA
48 internal hemorrhoid 10.0 ALK CD34
49 plexiform schwannoma 10.0 CD34 KIT
50 ewing's family of tumors 10.0 EWSR1 KIT

Graphical network of the top 20 diseases related to Mesenchymal Cell Neoplasm:



Diseases related to Mesenchymal Cell Neoplasm

Symptoms & Phenotypes for Mesenchymal Cell Neoplasm

GenomeRNAi Phenotypes related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.53 PDGFRA
2 Decreased viability GR00221-A-1 9.53 ALK KIT PDGFRA SMARCB1
3 Decreased viability GR00221-A-2 9.53 SMARCB1
4 Decreased viability GR00221-A-3 9.53 PDGFRA SMARCB1
5 Decreased viability GR00221-A-4 9.53 ALK PDGFRA
6 Decreased viability GR00301-A 9.53 KIT
7 Decreased viability GR00381-A-1 9.53 SMARCB1
8 Decreased viability GR00402-S-2 9.53 ALK KIT PDGFRA SMARCB1

Drugs & Therapeutics for Mesenchymal Cell Neoplasm

Drugs for Mesenchymal Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Cola Phase 3
4 Central Nervous System Depressants Phase 3
5 Adjuvants, Anesthesia Phase 3
6 Liver Extracts Phase 3
7 Anesthetics, Intravenous Phase 3
8 Analgesics, Opioid Phase 3
9 Peripheral Nervous System Agents Phase 3
10 Anesthetics, General Phase 3
11 Analgesics Phase 3
12 Narcotics Phase 3
13 Anesthetics Phase 3,Phase 2
14
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Lenograstim Approved, Investigational Phase 2 135968-09-1
17
Dactinomycin Approved, Investigational Phase 2 50-76-0 457193 2019
18
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
19
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
20
Epirubicin Approved Phase 2 56420-45-2 41867
21
Ifosfamide Approved Phase 2 3778-73-2 3690
22
Etoposide Approved Phase 2 33419-42-0 36462
23
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
24
Nintedanib Approved Phase 2 656247-17-5 56843413
25
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
26
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
27
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
28
Doxil Approved June 1999 Phase 2 31703
29 Mitogens Phase 2
30 Topoisomerase Inhibitors Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Anti-Bacterial Agents Phase 2
33
Isophosphamide mustard Phase 2 0
34 Immunosuppressive Agents Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 2
36 Nucleic Acid Synthesis Inhibitors Phase 2
37 Antineoplastic Agents, Alkylating Phase 2
38 Immunologic Factors Phase 2,Phase 1
39 Etoposide phosphate Phase 2
40 Alkylating Agents Phase 2
41 Antimitotic Agents Phase 2
42 Antirheumatic Agents Phase 2
43 Anti-Infective Agents Phase 2,Phase 1
44 Imatinib Mesylate Phase 2 220127-57-1 123596
45 Protein Kinase Inhibitors Phase 2
46 tyrosine Phase 2
47 Histone Deacetylase Inhibitors Phase 2
48 Antiviral Agents Phase 1, Phase 2
49 Antibodies Phase 1, Phase 2
50 Antibodies, Blocking Phase 1, Phase 2

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
3 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum Completed NCT00592345 Phase 1, Phase 2
5 Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) Completed NCT01172548 Phase 2 imatinib mesylate
6 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed NCT01874665 Phase 2 Ponatinib
7 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
8 Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia Recruiting NCT03736564 Phase 1, Phase 2
9 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
10 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
11 Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Recruiting NCT03109301 Phase 2 Selumetinib (AZD6244 hyd sulfate)
12 BGJ398 for the Treatment of Tumor-Induced Osteomalacia Recruiting NCT03510455 Phase 2 BGJ398
13 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Active, not recruiting NCT02015065 Phase 2 Vandetanib
14 Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) Withdrawn NCT02766842 Phase 2
15 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma Completed NCT01460901 Phase 1
16 NHS-IL12 for Solid Tumors Recruiting NCT01417546 Phase 1 NHS-IL-12
17 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia Unknown status NCT01524016 Early Phase 1 68Ga-DOTATATE
18 Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Unknown status NCT01660308
19 Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia Completed NCT00099762
20 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Completed NCT02884154 Not Applicable
21 the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal Tumor Recruiting NCT02763748 Not Applicable
22 Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal Tumors Recruiting NCT03601234 Not Applicable
23 The Clinical Relevance of Immune Cells and CTC in HNSCC Patients Recruiting NCT02420600
24 Doppler Ultrasound in Characterization of Superficial Soft Tissue Masses Not yet recruiting NCT03171857

Search NIH Clinical Center for Mesenchymal Cell Neoplasm

Genetic Tests for Mesenchymal Cell Neoplasm

Anatomical Context for Mesenchymal Cell Neoplasm

MalaCards organs/tissues related to Mesenchymal Cell Neoplasm:

41
Bone, Kidney, Liver, Lung, Skin, Spleen, Small Intestine

Publications for Mesenchymal Cell Neoplasm

Articles related to Mesenchymal Cell Neoplasm:

# Title Authors Year
1
A spontaneous mesenchymal cell neoplasm in the adult newt, Diemictylus viridescens. ( 5104322 )
1971

Variations for Mesenchymal Cell Neoplasm

Expression for Mesenchymal Cell Neoplasm

Search GEO for disease gene expression data for Mesenchymal Cell Neoplasm.

Pathways for Mesenchymal Cell Neoplasm

Pathways related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.15 CD34 CLTC FGF19 FGF23 KIT PDGFRA
2
Show member pathways
12.68 ALK FGF19 FGF23 KIT PDGFRA
3
Show member pathways
12.51 ALK FGF19 FGF23 PDGFRA
4 12.49 FGF19 FGF23 KIT PDGFRA
5
Show member pathways
12.48 FGF19 FGF23 KIT SMARCB1
6
Show member pathways
12.42 FGF19 FGF23 KIT PDGFRA
7
Show member pathways
12.4 FGF19 FGF23 KIT PDGFRA
8
Show member pathways
11.88 FGF19 FGF23 KIT PDGFRA
9
Show member pathways
11.85 ALK FGF19 FGF23 KIT PDGFRA
10 11.82 ALK FGF19 FGF23 KIT PDGFRA TPM3
11 11.78 ALK KIT PDGFRA
12 10.69 CALD1 TPM3 TPM4
13 10.56 ALK FGF19 FGF23 KIT PDGFRA
14 10.47 FGF23 PDGFRA

GO Terms for Mesenchymal Cell Neoplasm

Cellular components related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 muscle thin filament tropomyosin GO:0005862 8.62 TPM3 TPM4

Biological processes related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.89 ALK FGF23 KIT PDGFRA SMARCB1
2 protein autophosphorylation GO:0046777 9.65 ALK KIT PDGFRA
3 negative regulation of signal transduction GO:0009968 9.63 ALK KIT PDGFRA
4 MAPK cascade GO:0000165 9.62 FGF19 FGF23 KIT PDGFRA
5 muscle contraction GO:0006936 9.61 CALD1 TPM3 TPM4
6 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ALK FGF23 KIT PDGFRA
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.54 ALK KIT PDGFRA
8 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.51 KIT PDGFRA
9 positive regulation of protein kinase B signaling GO:0051897 9.46 FGF19 FGF23 KIT PDGFRA
10 positive regulation of phospholipase C activity GO:0010863 9.4 KIT PDGFRA
11 phosphatidylinositol phosphorylation GO:0046854 9.26 FGF19 FGF23 KIT PDGFRA
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.02 ALK FGF19 FGF23 KIT PDGFRA

Molecular functions related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.46 ALK FGF23 KIT PDGFRA
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 ALK KIT PDGFRA
3 fibroblast growth factor receptor binding GO:0005104 9.37 FGF19 FGF23
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 FGF19 FGF23 KIT PDGFRA
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 FGF19 FGF23 KIT PDGFRA
6 protein binding GO:0005515 10.13 ALK CALD1 CLTC EWSR1 FGF19 FGF23

Sources for Mesenchymal Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....